(Q83810300)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Trastuzumab resistance: all roads lead to SRC (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

Senthil K Muthuswamy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

416-418

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nm0411-416

27 January 2020

exact match

0 references

cites work

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

1 reference

12 December 2020

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Trastuzumab--mechanism of action and use in clinical practice

1 reference

12 December 2020

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

1 reference

12 December 2020

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

12 December 2020

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNM0411-416

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NM0411-416

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21475230%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference